United States Biotechnology & Medical Research

Arcellx Inc (ACLX)

Track

Arcellx Inc. experienced significant insider selling activity between January 14, 2026, and February 27, 2026. Key executives, including Rami Elghandour and Michelle Gilson, executed multiple sales of common stock. These transactions, which included both direct sales and proposed sales, represent the most recent insider trading activity recorded for the company.
Ticker: ACLX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Arcellx Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 27 Feb 2026
Value US$3,406,281.55 | Price 402.69 | Shares 86,542 (-24.7%)
Proposed sale 27 Feb 2026
Value US$2,306,657.34 | Price 233.69 | Shares 47,392
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-27 2026-02-27 S Sale
3.3
Elghandour Rami

SEE REMARKS

Executive Director
86,542 -24.7%
402.69
US$3,406,282 		86,542 -24.7% 402.69 US$3,406,282
2026-02-27 2026-02-27 PrS Proposed sale
3.3
Elghandour Rami

Officer; Director

Executive Director
47,392
233.69
US$2,306,657 		47,392 233.69 US$2,306,657
2026-02-25 2026-02-25 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
79,955 -21.5%
382.55
US$3,626,317 		79,955 -21.5% 382.55 US$3,626,317
2026-02-25 2026-02-25 PrS Proposed sale
2.8
Gilson Michelle

Officer

Officer
11,219
113.82
US$1,276,955 		11,219 113.82 US$1,276,955
2026-02-19 2026-02-19 PrS Proposed sale
2.8
Gilson Michelle

Officer

Officer
8,384
68.29
US$572,568 		8,384 68.29 US$572,568
2026-02-19 2026-02-19 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
100 -0.2%
69.38
US$6,938 		100 -0.2% 69.38 US$6,938
2026-02-19 2026-02-19 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
5,405 -10.7%
68.57
US$370,635 		5,405 -10.7% 68.57 US$370,635
2026-02-19 2026-02-19 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
2,879 -5.4%
67.73
US$194,995 		2,879 -5.4% 67.73 US$194,995
2026-02-18 2026-02-17 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
4,150 -7.2%
70.01
US$290,552 		4,150 -7.2% 70.01 US$290,552
2026-02-18 2026-02-17 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
7,141 -11.0%
69.21
US$494,231 		7,141 -11.0% 69.21 US$494,231
2026-02-17 2026-02-17 PrS Proposed sale
2.8
Gilson Michelle

Officer

Officer
11,291
69.51
US$784,782 		11,291 69.51 US$784,782
2026-01-20 2026-01-20 PrS Proposed sale
2.2
DAVID LUBNER

Director

Non-Executive Director
15,000
68.94
US$1,034,100 		15,000 68.94 US$1,034,100
2026-01-20 2026-01-20 PlS Planned sale
2.2
Lubner David Charles
Non-Executive Director
6,000 -21.7%
75.00
US$450,000 		6,000 -21.7% 75.00 US$450,000
2026-01-14 2026-01-14 PrS Proposed sale
2.3
Heery Christopher

Officer

Officer
5,882
68.51
US$402,997 		5,882 68.51 US$402,997
2026-01-14 2026-01-14 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
5,882 -19.9%
68.51
US$402,997 		5,882 -19.9% 68.51 US$402,997
2026-01-13 2026-01-13 PrS Proposed sale
2.3
Heery Christopher

Officer

Officer
7,437
65.51
US$487,213 		7,437 65.51 US$487,213
2026-01-13 2026-01-13 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
7,437 -20.1%
65.51
US$487,213 		7,437 -20.1% 65.51 US$487,213
2026-01-12 2026-01-12 PrS Proposed sale
2.3
Heery Christopher

Officer

Officer
6,131
64.15
US$393,286 		6,131 64.15 US$393,286
2026-01-12 2026-01-12 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
6,131 -14.2%
64.15
US$393,286 		6,131 -14.2% 64.15 US$393,286
2025-11-17 2025-11-17 PlS Planned sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
340 -54.5%
90.00
US$30,600 		340 -54.5% 90.00 US$30,600
2025-10-15 2025-10-15 PrS Proposed sale
2.8
MICHELLE GILSON

Officer

Officer
5,364
87.33
US$468,438 		5,364 87.33 US$468,438
2025-10-15 2025-10-15 PlS Planned sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
5,364 -38.8%
91.04
US$488,315 		5,364 -38.8% 91.04 US$488,315
2025-10-06 2025-10-06 PlS Planned sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
1,064 -7.1%
86.22
US$91,733 		1,064 -7.1% 86.22 US$91,733
2025-10-06 2025-10-03 PlS Planned sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
4,882 -24.7%
86.00
US$419,870 		4,882 -24.7% 86.00 US$419,870
2025-10-03 2025-10-03 PrS Proposed sale
2.8
MICHELLE GILSON

Officer

Officer
5,946
82.24
US$488,999 		5,946 82.24 US$488,999
2025-09-30 2025-09-30 PlS Planned sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
1,530 -71.0%
82.20
US$125,763 		1,530 -71.0% 82.20 US$125,763
2025-09-30 2025-09-30 PlS Planned sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
14,204 -86.8%
81.46
US$1,157,035 		14,204 -86.8% 81.46 US$1,157,035
2025-09-30 2025-09-30 PlS Planned sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
5,300 -24.5%
80.55
US$426,925 		5,300 -24.5% 80.55 US$426,925
2025-09-29 2025-09-29 PlS Planned sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
73 -0.3%
80.16
US$5,852 		73 -0.3% 80.16 US$5,852
2025-09-26 2025-09-26 PlS Planned sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
12,396 -36.3%
80.12
US$993,155 		12,396 -36.3% 80.12 US$993,155
2025-09-19 2025-09-19 PlS Planned sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
300 -0.9%
80.00
US$24,000 		300 -0.9% 80.00 US$24,000
2025-09-19 2025-09-18 PlS Planned sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
3,343 -8.9%
80.01
US$267,468 		3,343 -8.9% 80.01 US$267,468
2025-09-18 2025-09-18 PrS Proposed sale
2.3
CHRISTOPHER HEERY

Officer

Officer
37,486
76.42
US$2,864,680 		37,486 76.42 US$2,864,680
2025-06-11 2025-06-10 PlS Planned sale
Patel Kavita
Non-Executive Director
1,500 -100.0%
67.36
US$101,040 		1,500 -100.0% 67.36 US$101,040
2025-06-10 2025-06-10 PrS Proposed sale
KAVITA K PATEL

Director

Non-Executive Director
1,500
66.86
US$100,290 		1,500 66.86 US$100,290
2025-05-28 2025-05-27 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
8,449 -29.9%
64.38
US$543,909 		8,449 -29.9% 64.38 US$543,909
2025-05-28 2025-05-27 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
3,786 -11.8%
63.62
US$240,868 		3,786 -11.8% 63.62 US$240,868
2025-05-27 2025-05-27 PrS Proposed sale
2.8
Gilson Michelle

Officer

Officer
12,235
64.14
US$784,776 		12,235 64.14 US$784,776
2025-05-20 2025-05-20 PlS Planned sale
Patel Kavita
Non-Executive Director
1,500 -100.0%
58.43
US$87,645 		1,500 -100.0% 58.43 US$87,645
2025-04-29 2025-04-29 PrS Proposed sale
Yoon Derek

Director

Non-Executive Director
19,470
62.02
US$1,207,529 		19,470 62.02 US$1,207,529
2025-04-29 2025-04-29 PlS Planned sale
Patel Kavita
Non-Executive Director
1,500 -100.0%
64.20
US$96,300 		1,500 -100.0% 64.20 US$96,300
2025-04-08 2025-04-08 PlS Planned sale
Patel Kavita
Non-Executive Director
1,500 -100.0%
57.50
US$86,250 		1,500 -100.0% 57.50 US$86,250
2025-03-18 2025-03-18 PlS Planned sale
Patel Kavita
Non-Executive Director
1,500 -100.0%
71.64
US$107,460 		1,500 -100.0% 71.64 US$107,460
2025-02-26 2025-02-26 PrS Proposed sale
3.3
Elghandour Rami

Officer; Director

Executive Director
38,300
62.02
US$2,375,517 		38,300 62.02 US$2,375,517
2025-02-26 2025-02-26 S Sale
3.3
Elghandour Rami

SEE REMARKS

Executive Director
10,889 -6.8%
62.69
US$682,625 		10,889 -6.8% 62.69 US$682,625
2025-02-26 2025-02-26 S Sale
3.3
Elghandour Rami

SEE REMARKS

Executive Director
21,077 -11.6%
61.95
US$1,305,644 		21,077 -11.6% 61.95 US$1,305,644
2025-02-26 2025-02-26 S Sale
3.3
Elghandour Rami

SEE REMARKS

Executive Director
6,334 -3.4%
61.14
US$387,248 		6,334 -3.4% 61.14 US$387,248
2025-02-25 2025-02-25 PrS Proposed sale
KAVITA K PATEL

Director

Non-Executive Director
7,500
63.01
US$472,575 		7,500 63.01 US$472,575
2025-02-25 2025-02-25 PlS Planned sale
Patel Kavita
Non-Executive Director
1,500 -100.0%
63.16
US$94,740 		1,500 -100.0% 63.16 US$94,740
2025-02-24 2025-02-24 PrS Proposed sale
2.3
Heery Christopher

Officer

Officer
10,155
63.79
US$647,773 		10,155 63.79 US$647,773
2025-02-24 2025-02-24 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
208 -0.6%
64.88
US$13,495 		208 -0.6% 64.88 US$13,495
2025-02-24 2025-02-24 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
5,577 -12.9%
64.26
US$358,360 		5,577 -12.9% 64.26 US$358,360
2025-02-24 2025-02-24 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
4,370 -9.2%
63.14
US$275,918 		4,370 -9.2% 63.14 US$275,918
2025-02-04 2025-02-04 PlS Planned sale
Patel Kavita
Non-Executive Director
1,500 -100.0%
64.57
US$96,855 		1,500 -100.0% 64.57 US$96,855
2025-01-14 2025-01-14 PlS Planned sale
Patel Kavita
Non-Executive Director
300 -100.0%
67.32
US$20,195 		300 -100.0% 67.32 US$20,195
2025-01-14 2025-01-14 PlS Planned sale
Patel Kavita
Non-Executive Director
400 -57.1%
66.62
US$26,649 		400 -57.1% 66.62 US$26,649
2025-01-14 2025-01-14 PlS Planned sale
Patel Kavita
Non-Executive Director
800 -53.3%
64.95
US$51,957 		800 -53.3% 64.95 US$51,957
2025-01-10 2025-01-08 S Sale
3.3
Elghandour Rami

SEE REMARKS

Executive Director
13,837 -10.6%
73.69
US$1,019,689 		13,837 -10.6% 73.69 US$1,019,689
2025-01-10 2025-01-08 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
3,997 -29.4%
73.69
US$294,551 		3,997 -29.4% 73.69 US$294,551
2025-01-10 2025-01-08 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
3,553 -12.4%
73.69
US$261,831 		3,553 -12.4% 73.69 US$261,831
2025-01-10 2025-01-07 S Sale
3.3
Elghandour Rami

SEE REMARKS

Executive Director
16,474 -11.2%
75.53
US$1,244,253 		16,474 -11.2% 75.53 US$1,244,253
2025-01-10 2025-01-07 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
4,760 -26.0%
75.53
US$359,515 		4,760 -26.0% 75.53 US$359,515
2025-01-10 2025-01-07 PlS Planned sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
2,327 -11.3%
77.06
US$179,320 		2,327 -11.3% 77.06 US$179,320
2025-01-10 2025-01-07 PlS Planned sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
2,251 -9.8%
76.64
US$172,522 		2,251 -9.8% 76.64 US$172,522
2025-01-10 2025-01-07 PlS Planned sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
1,546 -6.3%
75.23
US$116,311 		1,546 -6.3% 75.23 US$116,311
2025-01-10 2025-01-07 PlS Planned sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
3,128 -11.3%
74.43
US$232,807 		3,128 -11.3% 74.43 US$232,807
2025-01-10 2025-01-07 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
4,230 -12.9%
75.53
US$319,485 		4,230 -12.9% 75.53 US$319,485
2025-01-07 2025-01-07 PrS Proposed sale
2.8
MICHELLE GILSON

Officer

Officer
9,252
75.01
US$693,993 		9,252 75.01 US$693,993
2025-01-07 2025-01-07 PrS Proposed sale
2.3
Heery Christopher

Officer

Officer
8,100
75.53
US$611,779 		8,100 75.53 US$611,779
2025-01-07 2025-01-07 PrS Proposed sale
2.8
Gilson Michelle

Officer

Officer
9,100
75.53
US$687,308 		9,100 75.53 US$687,308
2025-01-07 2025-01-07 PrS Proposed sale
3.3
Elghandour Rami

Officer; Director

Executive Director
32,000
75.53
US$2,416,906 		32,000 75.53 US$2,416,906
2025-01-06 2025-01-06 S Sale
2.8
Gilson Michelle

CHIEF FINANCIAL OFFICER

Officer
5,102 -15.3%
77.17
US$393,705 		5,102 -15.3% 77.17 US$393,705
2025-01-06 2025-01-06 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
3,061 -8.6%
77.17
US$236,208 		3,061 -8.6% 77.17 US$236,208
2025-01-06 2025-01-06 S Sale
2.3
Heery Christopher

CHIEF MEDICAL OFFICER

Officer
3,061 -8.6%
77.17
US$236,208 		3,061 -8.6% 77.17 US$236,208
2025-01-06 2025-01-06 S Sale
3.3
Elghandour Rami

SEE REMARKS

Executive Director
13,776 -8.5%
77.17
US$1,063,050 		13,776 -8.5% 77.17 US$1,063,050
Explore more

More insider trading research around Arcellx Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America